Replies to post #56093 on ViaDerma Inc (VDRM)

[bluebird50]

Your posting history adds up here.... lol

[fly_fisherman]

OK Whose ....


Shorting??? LOL

I have never had a MAJOR WINNER WITHOUT SOMEONE WITH CONCERNS!!! LOL

GLAD YOU SHOWED UP. FINAL INGREDIANT IN PLACE FOR A MASSIVE RUNNER!!!

[slops]

otcmonkey NO BUT You are ignoring the potential

[KeepItRealistic]

Missed the train I see lol

Don’t worry it hasn’t even left the station yet

C u at .10+ for starters

$VDRM buy & hold for .40+ target in 2021

No More Toxics, No Debt, No Dilution

CEO States no need for Toxic financing going forward!!!

Pink "Current"

Up List OTCQB coming!

Revenues today - CEO states "Just scratching the surface"

Target Markets in the Billions Worldwide!

FDA Approved IP - Patent Protected

State Expansion coming! (8 going to 50)

Major Health Insurance Carrier Approval - 100's of hospitals, etc. FOR STARTERS!

https://www.globenewswire.com/news-release/2021/01/13/2157661/0/en/ViaDerma-Inc-Provides-Review-of-2020-and-Looks-Forward-to-2021.html

* The FDA approved the registration of a new 55 ml Vitastem spray bottle. This came at the request of hospitals that have tested the product. A larger spray version will be easier to apply the medication to large wounds.

* Liberdol, a new relief pain product was officially launched in 2020. The analgesics market in the U.S. is estimated to be more than $12 billion dollars.

* An extended line of credit was secured for financing future manufacturing. We anticipate sales to top 500,000 units in 2021.

* A large national hospital chain and a major health insurance company have completed successful testing of the Vitastem product. We are now in the final stages of discussions to determine the size of the initial purchase.

* Successful product testing was completed by a major midwestern university with whom we are also in discussions regarding their initial product purchase.

* We have initiated discussions with a major global medical nonprofit that has expressed interest in purchasing Vitastem for use by their doctors and medical staff in treating patients.

—————————

a target projection of 500,000 units sold for 2021 was given. If reached, multiplying by $79/unit = $39.5 m in revenue x 50% margins) = 20m earnings. At 20x earnings (for this growth) = a 400m market cap/1B= $.40 share target

Vitastem – Powerful Super-Healing Topical Antibiotic for Treating Infections, Wounds, Diabetic Ulcers, Bed Sores, Burns, Rashes, Acne and many other skin conditions.

https://www.amazon.com/dp/B076V2RM46/ref=cm_sw_r_cp_api_glt_fabc_YP194M5C6ASR4NN8J99D

[sluggercjb]

I’m liking the green flag And this race Is just getting started it’s a long ways from The checkered flag : ) $1.00 or more : )

[westener]

I see no red flags here. I see nothing here that isn't an everyday happening in most young growing penny stocks. They all have hurdles to climb, and the successful ones find ways to do it.

Most penny stocks don't actually have any type of ongoing concern or business, but make a living selling shares. This company actually has salable products and one in particular that no one else has but all pharmaceutical companies will most likely want and eventually need in the future.

Stop creating red flags............if you can't stand the heat, get out of the fire.....get rid of your shares and please move on.